-$0.48 Earnings Per Share Expected for Sientra Inc (NASDAQ:SIEN) This Quarter
Equities research analysts expect that Sientra Inc (NASDAQ:SIEN) will report earnings per share of ($0.48) for the current quarter, according to Zacks Investment Research. Four analysts have made estimates for Sientra’s earnings, with the lowest EPS estimate coming in at ($0.60) and the highest estimate coming in at ($0.42). Sientra reported earnings of ($0.72) per share in the same quarter last year, which suggests a positive year over year growth rate of 33.3%. The business is scheduled to announce its next quarterly earnings report on Tuesday, November 5th.
According to Zacks, analysts expect that Sientra will report full year earnings of ($2.35) per share for the current financial year, with EPS estimates ranging from ($2.48) to ($2.27). For the next financial year, analysts expect that the company will post earnings of ($1.70) per share, with EPS estimates ranging from ($2.51) to ($1.36). Zacks’ EPS calculations are a mean average based on a survey of sell-side analysts that cover Sientra.
Sientra (NASDAQ:SIEN) last announced its earnings results on Thursday, August 8th. The medical instruments supplier reported ($1.19) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.69) by ($0.50). Sientra had a negative net margin of 151.96% and a negative return on equity of 123.80%. The business had revenue of $20.53 million during the quarter, compared to analyst estimates of $19.04 million. During the same period in the previous year, the company earned ($0.73) earnings per share. The business’s revenue for the quarter was up 17.0% on a year-over-year basis.
Shares of SIEN traded up $0.51 during trading on Tuesday, reaching $6.92. The company’s stock had a trading volume of 586,600 shares, compared to its average volume of 1,389,470. The company has a fifty day moving average of $5.91 and a two-hundred day moving average of $7.79. Sientra has a twelve month low of $4.78 and a twelve month high of $26.65. The company has a market cap of $315.95 million, a price-to-earnings ratio of -2.13 and a beta of 0.29. The company has a quick ratio of 1.16, a current ratio of 2.33 and a debt-to-equity ratio of 0.18.
In other news, CFO Paul Sean Little purchased 17,391 shares of the stock in a transaction dated Friday, June 7th. The stock was acquired at an average cost of $5.75 per share, for a total transaction of $99,998.25. Following the acquisition, the chief financial officer now owns 94,891 shares of the company’s stock, valued at $545,623.25. The acquisition was disclosed in a filing with the SEC, which is available at this link. Also, Director Keith J. Sullivan purchased 20,869 shares of the stock in a transaction dated Friday, June 7th. The stock was purchased at an average price of $5.75 per share, with a total value of $119,996.75. Following the completion of the acquisition, the director now directly owns 203,141 shares in the company, valued at approximately $1,168,060.75. The disclosure for this purchase can be found here. 13.30% of the stock is currently owned by insiders.
Several hedge funds and other institutional investors have recently modified their holdings of SIEN. Schroder Investment Management Group bought a new stake in shares of Sientra in the 2nd quarter valued at approximately $7,700,000. UBS Group AG grew its stake in Sientra by 37.9% during the 2nd quarter. UBS Group AG now owns 2,657,863 shares of the medical instruments supplier’s stock worth $16,372,000 after buying an additional 730,475 shares during the last quarter. Vanguard Group Inc. grew its stake in Sientra by 64.4% during the 2nd quarter. Vanguard Group Inc. now owns 1,857,953 shares of the medical instruments supplier’s stock worth $11,445,000 after buying an additional 727,906 shares during the last quarter. Marshall Wace LLP grew its stake in Sientra by 6,998.6% during the 2nd quarter. Marshall Wace LLP now owns 710,142 shares of the medical instruments supplier’s stock worth $4,375,000 after buying an additional 700,138 shares during the last quarter. Finally, Citadel Advisors LLC grew its stake in Sientra by 421.7% during the 2nd quarter. Citadel Advisors LLC now owns 450,910 shares of the medical instruments supplier’s stock worth $2,778,000 after buying an additional 364,473 shares during the last quarter. Institutional investors and hedge funds own 86.93% of the company’s stock.
Sientra, Inc, a medical aesthetics company, develops and sells medical aesthetics products to plastic surgeons in the United States. It operates through two segments, Breast Products and miraDry. The company offers silicone gel breast implants for use in breast augmentation and breast reconstruction procedures; breast tissue expanders; and scar management products under the Sientra, AlloX2, Dermaspan, Softspan, and BIOCORNEUM brand names.
See Also: What is Compound Interest?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Sientra Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sientra and related companies with MarketBeat.com's FREE daily email newsletter.